Skip to Content
Merck
All Photos(5)

Key Documents

WH0003845M1

Sigma-Aldrich

Monoclonal Anti-KRAS antibody produced in mouse

clone 3B10-2F2, purified immunoglobulin, buffered aqueous solution

Synonym(s):

KRAS Antibody - Monoclonal Anti-KRAS antibody produced in mouse, Kras Antibody, Anti-CKRAS, Anti-KIRAS, Anti-KRAS1, Anti-KRAS2, Anti-KRAS2A, Anti-KRAS2B, Anti-KRAS4A, Anti-KRAS4B, Anti-RASK2, Anti-v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

3B10-2F2, monoclonal

form

buffered aqueous solution

species reactivity

human

technique(s)

ELISA: suitable
capture ELISA: suitable
immunofluorescence: suitable
western blot: 1-5 μg/mL

isotype

IgG1κ

GenBank accession no.

UniProt accession no.

application(s)

research pathology

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... KRAS(3845)

Related Categories

General description

Kirsten rat sarcoma viral oncogene homologue (KRAS) is an oncogene that is mapped to human chromosome 12p12.1. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. The gene codes for a member of the small GTPase superfamily.

Immunogen

KRAS (AAH13572, 1 a.a. ~ 188 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Sequence
MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGHEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEKMSKDGKKKKKKSKTKCVIM

Application

Monoclonal Anti-KRAS antibody produced in mouse has been used in immunoprecipitation, immunofluorescence, western blotting, indirect enzyme linked immunosorbent assay (ELISA).

Biochem/physiol Actions

Kirsten rat sarcoma viral oncogene homologue (KRAS) is a key protein of the Ras signaling pathways. It facilitates the invasion and metastasis of tumors. Gain-of-function mutations in the gene leads to the development of variety of tumors, including pancreatic, biliary tract and colon tumors. This mutation is rarely observed in gastric cancer.

Physical form

Solution in phosphate buffered saline, pH 7.4

Legal Information

GenBank is a registered trademark of United States Department of Health and Human Services

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
Waters AM, et al.
Science Signaling, 10, 84826-84826 (2017)
A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth
Mita H, et al.
BMC Cancer, 9, 1-16 (2009)
Eusebio Manchado et al.
Nature, 534(7609), 647-651 (2016-06-25)
Therapeutic targeting of KRAS-mutant lung adenocarcinoma represents a major goal of clinical oncology. KRAS itself has proved difficult to inhibit, and the effectiveness of agents that target key KRAS effectors has been thwarted by activation of compensatory or parallel pathways
Frontiers in neurology and neuroscience research null
Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer
Uchiyama M, et al.
International Journal of Cancer. Journal International Du Cancer, 107, 962-969 (2003)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service